Adam Karpman, DO
Cardiovascular Disease · Portland, MENPI 1093002750
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,505 of the $6,553 with a category attached, or 84.0%. Novartis accounts for 90.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $6,119 and has fallen 98.9% since, to $65 in 2022. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $297.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Medtronic$172
- Abbott$169
- Edwards Lifesciences$123
- Boston Scientific$95
- Johnson & Johnson$25
- plus $56 from 3 others
What the payments were for
- Speaking & faculty fees$5,50584%
- Food & beverage$1,04816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $5,913 |
| Medtronic | 2 | $172 |
| Abbott | 2 | $169 |
| Edwards Lifesciences | 4 | $123 |
| Boston Scientific | 1 | $95 |
| Johnson & Johnson | 1 | $25 |
| AstraZeneca | 1 | $23 |
| Pfizer | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$5,879
- HeartMate$145
- CoreValve Evolut$144
How this compares
$6,553 in reported general payments places this provider in the 90th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $291,484 |
| XareltoRivaroxaban | 39 | $48,276 |
| Repatha SureclickEvolocumab | 61 | $39,419 |
| Praluent PenAlirocumab | 11 | $5,154 |
| Rosuvastatin Calcium | 68 | $3,010 |
| Metoprolol Succinate | 133 | $2,145 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $1,179 |
| Carvedilol | 78 | $831 |
| Metoprolol Tartrate | 65 | $506 |
| Amlodipine Besylate | 44 | $421 |
| Nitroglycerin | 31 | $392 |
| Atorvastatin Calcium | 50 | $373 |
| Amiodarone Hcl | 30 | $326 |
| Digoxin | 11 | $311 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $291,484239 claims |
| Johnson & JohnsonXarelto | $25 | $48,27639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 cardiovascular disease providers in Maine.
Other cardiovascular disease in Portland
- Bram GellerPortland$5K
- Benjamin StarobinPortland$3K
- Sebastian JablonskiPortland$528
- Craig BrettPortland$294
- Charles HoagPortland$105
- Ronald RosenfeldPerry$51K
- Jonathan HalevyAugusta$22K
- Jeffrey ColnesYork$22K
- Howard GlassWestbrook$13K
- Jaidip ChakravarttiScarborough$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.